The 5th China Healthcare Investment Conference (CHIC) was held on March 4-6, 2014 in Shanghai. Dr. Zhenkun Ma, Founder and CEO of TenNor Therapeutics, was invited to speak at the conference and share TenNor’s product portfolio and development strategy. First held in 2010, CHIC was a joint effort by a group of world-class investors who had recognized that the healthcare reform and economic growth in China were spurring a new wave of emerging Chinese healthcare companies. Now in its 5th year, CHIC has established itself as the preeminent platform to promote and nurture the Chinese healthcare investment ecosystem and further develop the biotechnology industry.

About TenNor Therapeutics

Incorporated in 2013, TenNor Therapeutics is a near-commercial stage biotechnology company dedicated to the discovery, development and commercialization of differentiated therapies to address unmet medical needs in disease areas associated with bacterial infections and bacterial metabolism. Empowered by its proprietary multi-targeting conjugate molecule technology, TenNor Therapeutics aims to deliver the best therapeutic solutions to overcome the limitations of conventional treatments and improve patient outcomes. As of July 24, 2025, TenNor Therapeutics had built a differentiated pipeline of seven innovative assets, including three Core Products, namely, rifasutenizol (TNP-2198), the world’s first and only new molecular entity (“NME”) drug candidate developed for the treatment of Helicobacter pylori (“H. pylori”) infection; rifaquizinone (TNP-2092) injection, a potential first-in-class, triple-targeting antibacterial drug candidate for the treatment of implant-associated bacterial infections; and TNP-2092 oral, the world’s first multi-targeting antibacterial drug candidate for the treatment of diseases associated with gut bacterial metabolism.

For more information, please visit: www.tennortherapeutics.com